XIAMEN AMOYTOP BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.51 CNY | -0.31% |
|
-6.43% | +15.59% |
| 04-22 | Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-18 | China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6% | MT |
| Sales 2024 * | 2.81B 388M 534M | Sales 2025 * | 3.69B 510M 702M | Capitalization | 24.62B 3.4B 4.68B |
|---|---|---|---|---|---|
| Net income 2024 * | 754M 104M 143M | Net income 2025 * | 1.03B 143M 196M | EV / Sales 2024 * | 8.75 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 6.67 x |
| P/E ratio 2024 * |
32.6
x | P/E ratio 2025 * |
23.8
x | Employees | 1,960 |
| Yield 2024 * |
0.21% | Yield 2025 * |
0.61% | Free-Float | 31.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.31% | ||
| 1 week | -6.43% | ||
| Current month | -2.32% | ||
| 1 month | -2.32% | ||
| 3 months | +16.59% | ||
| 6 months | +40.20% | ||
| Current year | +15.59% |
1 week
58.31
62.94
1 month
57.5867.20
Current year
47.3569.97
1 year
31.0169.97
3 years
21.3269.97
5 years
21.3281.50
10 years
21.3281.50
| Managers | Title | Age | Since |
|---|---|---|---|
Li Sun
CEO | Chief Executive Officer | 58 | 13-04-30 |
Yi Ling Yang
DFI | Director of Finance/CFO | 49 | 97-06-30 |
Shi Yuan Wang
CTO | Chief Tech/Sci/R&D Officer | 51 | 00-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Na Jia
BRD | Director/Board Member | 57 | 18-07-31 |
Chun Lan
BRD | Director/Board Member | 58 | 00-03-31 |
Li Sun
CEO | Chief Executive Officer | 58 | 13-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.90% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 60.51 | -0.31% | 2 119 454 |
| 24-04-29 | 60.7 | -1.04% | 2,551,557 |
| 24-04-26 | 61.34 | +3.09% | 2,114,848 |
| 24-04-25 | 59.5 | -0.58% | 2,158,973 |
| 24-04-24 | 59.85 | +0.59% | 2,635,627 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
60.51
CNY
Average target price
89.2
CNY
Spread / Average Target
+47.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.59% | 3.41B | |
| -3.45% | 87.17B | |
| +2.76% | 40.1B | |
| -17.30% | 31.38B | |
| +57.86% | 25.12B | |
| -16.06% | 15.59B | |
| -9.12% | 12B | |
| -42.56% | 11.8B | |
| -17.90% | 11.8B | |
| +6.89% | 8.81B |
- Stock Market
- Equities
- 688278 Stock
